Such studies are strongly needed not only to confirm our findings but also to investigate gene–gene and gene–environment interactions, along with the adjustment of confounding factors, for the association of CYP2C19 genotype with efficacy and safety of clopidogrel in patients with stroke or TIA. The gene discussed is CYP2C19; the disease is Stroke.